Lasiokaurin
Based on 1 publication(s) in Google Scholar
Lasiokaurin is an anticancer agent. Lasiokaurin can be isolated from Rabdosia rubescens (Hemsl.) H. Hara. Lasiokaurin inhibits the function of the PDPK1-AKT axis, with a Kd value of 75.93 μM for PDPK1. Lasiokaurin inhibits mTOR, STAT3, MAPK and NF-κB. Lasiokaurin reduces the mRNA and protein expression levels of PLK1. Lasiokaurin decreases DNA synthesis levels, induces cell Apoptosis, and regulates Autophagy processes. Lasiokaurin inhibits tumor growth in xenograft models. Lasiokaurin can be used in research related to nasopharyngeal carcinoma, triple-negative breast cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.68%
- CAS. Nr.: 28957-08-6
- Formel: C22H30O7
- Molecular Weight:406.47
-
Speicherung:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Lasiokaurin
MoreAlle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
PLK1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
10.9 μM
Compound: 8
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| A549 | IC50 |
13.47 μM
Compound: 6
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| A549 | IC50 |
6.7 μM
Compound: 19
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| A549 | IC50 |
7.6 μM
Compound: 13
|
Cytotoxicity against human A549 cells after 48 hrs by MTT method
Cytotoxicity against human A549 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| B16 | IC50 |
32.57 μM
Compound: 5
|
Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| Bel-7402 | IC50 |
3.59 μM
Compound: 6
|
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| HCT-116 | IC50 |
13.48 μM
Compound: 5
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| HepG2 | IC50 |
11.94 μM
Compound: 5
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| HepG2 | IC50 |
5.67 μM
Compound: 8
|
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| HL-60 | IC50 |
1.8 μM
Compound: 19
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| HL-60 | IC50 |
3.2 μM
Compound: 13
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT method
Cytotoxicity against human HL60 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| K562 | IC50 |
4.92 μM
Compound: 6
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| K562 | IC50 |
521 μM
Compound: 5
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| L02 | IC50 |
22.36 μM
Compound: 6
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| L02 | IC50 |
25.39 μM
Compound: 5
|
Cytotoxicity against human L02 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| MCF7 | IC50 |
19.82 μM
Compound: 5
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| MCF7 | IC50 |
2.5 μM
Compound: 19
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| MCF7 | IC50 |
5.3 μM
Compound: 13
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT method
Cytotoxicity against human MCF7 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| PBMC | IC50 |
>50 μM
Compound: 5
|
Cytotoxicity against human PBMC cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human PBMC cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| PBMC | IC50 |
>50 μM
Compound: 6
|
Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| RAW264.7 | IC50 |
1.9 μM
Compound: 19
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method
|
[PMID: 23819871] |
| RPMI-8226 | IC50 |
11.03 μM
Compound: 8
|
Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| SGC-7901 | IC50 |
6.45 μM
Compound: 6
|
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| SMMC-7721 | IC50 |
2 μM
Compound: 13
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT method
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| SMMC-7721 | IC50 |
2.7 μM
Compound: 19
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| SW480 | IC50 |
2.3 μM
Compound: 13
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT method
Cytotoxicity against human SW480 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| SW480 | IC50 |
2.4 μM
Compound: 19
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
In Vitro
Lasiokaurin (0.19-50 μM; 24-72 h) dose- and time-dependently inhibits the viability of CNE-1, CNE-2, and C666-1 nasopharyngeal carcinoma cells in vitro[1].
Lasiokaurin (0.5-2 μM; 7 days) dose-dependently inhibits the colony formation of CNE-1 and CNE-2 nasopharyngeal carcinoma cells in vitro, with significant inhibition observed at concentrations as low as 0.5 μM[1].
Lasiokaurin (2.5-10 μM; 24 h) dose-dependently inhibits the activation of MAPK, mTOR, STAT3, and NF-κB pathways in CNE-1 and CNE-2 nasopharyngeal carcinoma cells in vitro, including inhibition of both mTORC1 and mTORC2 complexes[1].
Lasiokaurin (0.2-50 μM; 24-72 h) potently inhibits viability of MDA-MB-231, MDA-MB-468, and MCF7 breast cancer cells with IC50 values ranging from 1.6 μM to 8.35 μM across 24-72 h, and exhibits lower toxicity to MCF-10A normal breast cells[2].
Lasiokaurin (72 h) potently inhibits the viability of SK-BR-3, MDA-MB-231, BT-549, MCF-7, and T-47D human breast cancer cells with IC50 values ranging from 1.59 μM to 4.16 μM after 72 h of treatment[3].
Lasiokaurin (0.3-3 μM) inhibits the viability of patient-derived xenograft breast cancer organoids in a concentration-dependent manner[3].
Lasiokaurin (2.5-10 μM; 24-48 h) induces dose- and time-dependent G2/M cell cycle arrest in CNE-1 and CNE-2 nasopharyngeal carcinoma cells in vitro by reducing cyclin B1 and cdc2 expression[1].
Lasiokaurin (2.5-10 μM; 24 h) dose-dependently induces apoptosis in CNE-1 and CNE-2 nasopharyngeal carcinoma cells in vitro by increasing Bax expression[1].
Lasiokaurin (2.5-5 μM; 12-48 h) dose- and time-dependently inhibits the migration of CNE-1 and CNE-2 nasopharyngeal carcinoma cells in vitro[1].
Lasiokaurin (2.5-10 μM; 24-48 h) at concentrations of 2.5-10 μM induces DNA damage in MDA-MB-231 and MDA-MB-468 TNBC cells by suppressing PARP expression after 24 and 48 h of treatment[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:CNE-1, CNE-2, C666-1
-
Concentration:0.19-50 μM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Caused a significant dose- and time-dependent reduction in cell viability across all three NPC cell lines.
Inhibited cell viability with statistically significant effects (p < 0.05, p < 0.001) observed at multiple concentration-time combinations.
-
Cell Line:CNE-1, CNE-2
-
Concentration:2.5-10 μM
-
Incubation Time:24 h; 48 h
-
Result:Caused a dose- and time-dependent increase in the proportion of cells in the G2/M phase.
Reduced cyclin B1 and cdc2 protein expression in both cell lines at 2.5, 5, and 10 μM (24 h incubation), with statistically significant decreases observed at 5 μM and 10 μM (p < 0.05, p < 0.01).
-
Cell Line:CNE-1, CNE-2
-
Concentration:2.5-10 μM
-
Incubation Time:24 h
-
Result:Caused a dose-dependent increase in the percentage of apoptotic cells (early and late apoptosis) in both cell lines.
Increased Bax expression in CNE-1 cells at 2.5 μM, 5 μM, and 10 μM, with significant elevations at 5 μM and 10 μM (p < 0.01).
Increased Bax expression in CNE-2 cells at 2.5 μM, 5 μM, and 10 μM, with significant elevations at 5 μM (p < 0.05) and 10 μM (p < 0.01).
-
Cell Line:CNE-1, CNE-2
-
Concentration:2.5-5 μM
-
Incubation Time:12 h; 24 h; 36 h; 48 h
-
Result:Caused a dose- and time-dependent reduction in relative wound healing rates in both cell lines.
Resulted in significantly lower wound healing rates compared to controls at all time points with 5 μM Lasiokaurin, with 2.5 μM Lasiokaurin also showing inhibitory effects.
-
Cell Line:CNE-1, CNE-2
-
Concentration:2.5-10 μM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced phosphorylation of Erk1/2, p38, mTOR, STAT3, and NF-κB in both cell lines, with significant decreases observed at multiple concentrations (p < 0.05, p < 0.01).
Reduced expression of Rictor, Raptor, and Gβl (components of mTORC1 and mTORC2) in both cell lines, with significant decreases at 5 μM and 10 μM (p < 0.05, p < 0.01).
In Vivo
Lasiokaurin (5-10 mg/kg; i.p.; daily; 20 days) significantly inhibits triple-negative breast cancer xenograft tumor growth in BALB/c nude mice, with the 10 mg/kg dose showing efficacy comparable to docetaxel and no detectable toxicity to vital organs or body weight[2].
Lasiokaurin (7.5-15 mg/kg; i.p.; once every 2 days; 27 days) inhibits breast cancer growth in vivo by suppressing PLK1 pathway signaling, with 15 mg/kg lasiokaurin significantly reducing tumor volume, tumor weight, and cell proliferation while inducing apoptosis, without causing significant body weight loss[3].
Lasiokaurin (25 mg/kg; i.p.; once every two days) significantly inhibits breast cancer xenograft growth in nude mice by activating autophagy, inhibiting the AKT/mTOR signaling pathway, and suppressing glycolytic activity, with no observed toxicity[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (female, housed at 23°C with 12 h light/dark cycle)[2]
-
Dosage:5 mg/kg; 10 mg/kg
-
Administration:i.p.; daily; 20 days
-
Result:Significantly reduced tumor volume and tumor weight relative to the vehicle group.
Showed slightly lower efficacy than docetaxel at 5 mg/kg.
Demonstrated comparable efficacy to docetaxel at 10 mg/kg.
Caused no significant effect on mouse body weight.
Showed no notable alterations in organ weight or histopathological characteristics of heart, lung, liver, spleen, or kidney relative to the vehicle group.
-
Animal Model:Balb/c nude (female, 5 weeks old, 18-22 g, subcutaneous xenograft model)[3]
-
Dosage:7.5 mg/kg; 15 mg/kg
-
Administration:i.p.; once every 2 days; 27 days
-
Result:Significantly reduced tumor volume and tumor weight at 15 mg/kg compared to vehicle controls.
Showed no significant body weight loss relative to vehicle controls.
Significantly reduced Ki67 expression in tumor tissue.
Significantly increased TUNEL-positive cells in tumor tissue.
Downregulated tumor tissue protein levels of PLK1, CDC25C, CyclinB1, CDC2, and p-AKT relative to total AKT.
-
Animal Model:Nude mice (female, six-week-old)[4]
-
Dosage:25 mg/kg
-
Administration:i.p.; once every two days; 9 total doses
-
Result:Significantly reduced xenograft tumor growth compared to PBS control, with lower final tumor weights and slower tumor volume progression over 18 days.
Reduced Ki67-positive proliferating cells in tumor tissues.
Increased TUNEL-positive apoptotic cells and necrotic area in tumor tissues.
Increased LC3II levels in tumor tissues.
Decreased PDPK1 expression in tumor tissues.
Increased protein levels of p62, beclin1, ATG5, and LC3II in tumor tissues.
Decreased phosphorylated levels of AKT, mTOR, and p70S6K in tumor tissues.
Reduced protein levels of glycolysis-related markers HK2, GLUT1, GLUT3, and LDHA in tumor tissues.
Maintained stable mouse body weights with no treatment-related damage observed in heart, liver, spleen, lung, and kidney via H&E staining.
Chemical Information
-
CAS. Nr. 28957-08-6
-
Appearance Solid
-
Molecular Weight 406.47
-
Formel C22H30O7
-
Color White to off-white
-
SMILES
O[C@]1(OC2)[C@]([C@@H]3O)(C4=O)[C@](CC[C@H]3C4=C)([H])[C@]2([C@H](CC5)OC(C)=O)[C@](C5(C)C)([H])[C@@H]1O
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biochem Pharmacol
Lasiokaurin suppresses breast cancer growth by blocking autophagic flux and regulating cellular energy homeostasis. [Abstract]2025 Aug 7;242(Pt 3):117212. PMID: 40782951
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (246.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Reinheit & Dokumentation
-
Data Sheet (320 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[2]. Lin J, et al. In Vitro and In Vivo Anti-Cancer Activity of Lasiokaurin in a Triple-Negative Breast Cancer Model. Molecules (Basel, Switzerland). 2023 Nov 22;28(23):7701. [Content Brief]
[3]. Liu Z, et al. Lasiokaurin Regulates PLK1 to Induce Breast Cancer Cell G2/M Phase Block and Apoptosis. Journal of Cancer. 2024;15(8):2318-2328. [Content Brief]
[4]. Huang R, et al. Lasiokaurin suppresses breast cancer growth by blocking autophagic flux and regulating cellular energy homeostasis. Biochemical pharmacology. 2025 Dec;242(Pt 3):117212. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4602 mL | 12.3010 mL | 24.6021 mL | 61.5052 mL |
| 5 mM | 0.4920 mL | 2.4602 mL | 4.9204 mL | 12.3010 mL | |
| 10 mM | 0.2460 mL | 1.2301 mL | 2.4602 mL | 6.1505 mL | |
| 15 mM | 0.1640 mL | 0.8201 mL | 1.6401 mL | 4.1003 mL | |
| 20 mM | 0.1230 mL | 0.6151 mL | 1.2301 mL | 3.0753 mL | |
| 25 mM | 0.0984 mL | 0.4920 mL | 0.9841 mL | 2.4602 mL | |
| 30 mM | 0.0820 mL | 0.4100 mL | 0.8201 mL | 2.0502 mL | |
| 40 mM | 0.0615 mL | 0.3075 mL | 0.6151 mL | 1.5376 mL | |
| 50 mM | 0.0492 mL | 0.2460 mL | 0.4920 mL | 1.2301 mL | |
| 60 mM | 0.0410 mL | 0.2050 mL | 0.4100 mL | 1.0251 mL | |
| 80 mM | 0.0308 mL | 0.1538 mL | 0.3075 mL | 0.7688 mL | |
| 100 mM | 0.0246 mL | 0.1230 mL | 0.2460 mL | 0.6151 mL |